Results 51 to 60 of about 24,314 (291)
A Survey on Identity-Based Blind Signature
, 2023 Blind signatures are well-studied building blocks of cryptography, originally designed to enable anonymity in electronic voting and digital banking. Identity-based signature were introduced by Shamir in 1984 and gave an alternative to prominent Public Key Infrastructure. An identity-based blind signature (IDBS) allows any user to interact directly with
Mirko Koscina +4 more
openaire +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak +4 more
wiley +1 more source
Added Prognostic Value of EEG Reactivity in Comatose Patients Following Cardiac Arrest
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives To evaluate the added prognostic value of EEG reactivity for favorable outcome compared with background analysis during and after targeted temperature management (TTM). Methods Prospective observational cohort study of comatose post–cardiac arrest patients admitted to a single academic center between 2017 and 2022, all undergoing ...
Sarah Caroyer +11 more
wiley +1 more source
Two improved partially blind signature schemes from bilinear pairings [PDF]
, 2005 A blind signature scheme is a protocol for obtaining a digital signature from a signer, but the signer can neither learn the messages he/she sign nor the signatures the recipients obtain afterwards.
Hui, LCK, Chow, KP, Chow, SSM, Yiu, SM
core +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
Untraceable Blind Signature Schemes Based on the Discrete Logarithm Problem
, 2010 [[abstract]]With the help of a blind signature scheme, a requester can obtain a signature on a message from a signer such that the signer knows nothing about the content of the messages and is unable to link the resulting message-signature pair; namely ...
Cheng-Chi Lee; Min-Shiang Hwang; Wei-Pang Yang
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Blind signature scheme based on entangled quantum
Tongxin xuebao, 2016 Based on the principle of quantum entanglement swapping, a blind signature scheme based on quantum entanglement was proposed.Through being entangled and exchanged, particles prepared before could transform into entangled state.
Jian-wu LIANG +3 more
doaj +2 more sources
Untraceable Blind Signature Schemes Based on the Discrete Logarithm Problem
, 2012 [[abstract]]With the help of a blind signature scheme, a requester can obtain a signature on a message from a signer such that the signer knows nothing about the content of the messages and is unable to link the resulting message-signature pair; namely ...
Cheng-Chi Lee;Wei-Pang Yang;Min-Shiang Hwang
core
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source